

## 21 Community Clusters

12 in Zambia / 9 in South Africa

Average of approx. 55,000 individuals in each cluster  
Approximately 600,000 total adults across all communities

### Randomization

#### Arm A

Clusters: 4 Zambia / 3 South Africa

#### Intervention

**Combination prevention** including:

- Universal household-based testing
- Active linkage to care
- Immediate* ART eligibility

#### Evaluation

##### **Population Cohort A**

One adult from each of 2,500 randomly selected households in each cluster

##### **Health Centre Data A**

Routinely collected data from Health Centres in the community

##### **CHiPs Data A**

Data collected from community members during household visits

#### Arm B

Clusters: 4 Zambia / 3 South Africa

#### Intervention

**Combination prevention** including:

- Universal household-based testing
- Active linkage to care
- ART eligibility *according to national guidelines*

#### Evaluation

##### **Population Cohort B**

One adult from each of 2,500 randomly selected households in each cluster

##### **Health Centre Data B**

Routinely collected data from Health Centres in the community

##### **CHiPs Data B**

Data collected from community members during household visits

#### Arm C

Clusters: 4 Zambia / 3 South Africa

#### Standard of Care

**Control Arm:**

- Existing prevention & testing services and referral for care
- ART eligibility *according to national guidelines*

#### Evaluation

##### **Population Cohort C**

One adult from each of 2,500 randomly selected households in each cluster

##### **Health Centre Data C**

Routinely collected data from Health Centres in the community

### Primary Outcome Measure

- HIV incidence measured over 3 years in **Population Cohort (from Arms A, B and C)**

### Secondary Outcome Measures

- Population Cohort:** HIV incidence measured over 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> years, HSV-2 incidence, sexual risk behaviour, community VL\*, viral suppression (ART patients)\*, drug resistance (ART patients with detectable VL)\*
- Population Cohort and Health Centre Data:** ART Adherence, HIV disease progression and death, ART toxicity, HIV stigma
- Health Centre Data:** TB notification and TB mortality rates
- Population Cohort, Health Centre Data, CHiPs Data:** uptake of PMTCT, uptake of male circumcision, ART screening and uptake, uptake of HIV testing and retesting, time between diagnosis and initiation of care

\* Subject to funding for these assays.